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Nanoscale drug delivery vehicles can facilitate multimodal therapies of cancer by promoting tumour-selective drug release.
However, few are effective because cancer cells develop ways to resist and evade treatment. Here, we introduce a
photoactivable multi-inhibitor nanoliposome (PMIL) that imparts light-induced cytotoxicity in synchrony with a
photoinitiated and sustained release of inhibitors that suppress tumour regrowth and treatment escape signalling
pathways. The PMIL consists of a nanoliposome doped with a photoactivable chromophore (benzoporphyrin derivative,
BPD) in the lipid bilayer, and a nanoparticle containing cabozantinib (XL184)—a multikinase inhibitor—encapsulated
inside. Near-infrared tumour irradiation, following intravenous PMIL administration, triggers photodynamic damage of
tumour cells and microvessels, and simultaneously initiates release of XL184 inside the tumour. A single PMIL treatment
achieves prolonged tumour reduction in two mouse models and suppresses metastatic escape in an orthotopic pancreatic
tumour model. The PMIL offers new prospects for cancer therapy by enabling spatiotemporal control of drug release while
reducing systemic drug exposure and associated toxicities.
1Nanoscale drug delivery systems enable controlled drug release2 with increased tumour selectivity and reduced toxicity1.3 Recently, multifunctional nanoparticles activated by external
4 stimuli have emerged to enhance tumour-selective drug release1.
5 These activable delivery vehicles include optically responsive nano-
6 materials that support a broad range of biophotonic therapy and
7 imaging applications2–4, offering great promise for facilitating multi-
8 modal therapies of cancer. However, a fundamental challenge in
9 oncology is that a number of resistance mechanisms and escape
10 pathways ultimately limit treatment efﬁcacy5,6.
11 Here, we report near-infrared (NIR) light-activated PMILs that
12 impart photocytotoxicity to multiple tumour compartments and
13 enable photoinitiated, sustained release of a multimolecular inhibi-
14 tor with potent antiangiogenic activity and suppression of promi-
15 nent treatment escape pathways (Fig. 1a). This unique approach
16 impairs multiple, distinct molecular targets and is motivated by a
17 three-way mechanistic interaction to combine: (i) photodynamic
18 therapy (PDT)-induced tumour cell apoptotic signalling with
19 XL184 inhibition of anti-apoptotic signalling pathways that
20 promote cell survival; (ii) PDT-induced microvessel damage with
21 sustained XL184 inhibition of vascular endothelial growth factor
22 (VEGF) signalling to suppress tumour angiogenesis and vascular
23 regrowth; and (iii) exploiting a second molecular target of XL184,
24 sustained inhibition of MET—the receptor tyrosine kinase for hep-
25 atocyte growth factor—signalling to suppress cancer cell motility,
26 invasion and metastatic escape in response to tumour hypoxia
27induced by vascular damage and antiangiogenic therapy7,8. We
28show that BPD–XL184 PMILs realize these complementary inter-
29actions, resulting in enhanced tumour reduction in vivo in two
30mouse models of human pancreatic ductal adenocarcinoma
31(PDAC). In contrast to the corresponding monotherapies and com-
32bination therapy using conventional drug formulations, a single
33treatment cycle using PMILs results in prolonged local tumour
34control in a subcutaneous and in an orthotopic PDAC
35mouse model.
36VEGF and MET are prime examples of tumour signalling path-
37ways that promote treatment escape. VEGF and its receptors (for
38example VEGFR2) represent key targets for antiangiogenic
39therapy, and upregulation of VEGF signalling has been observed
40in response to radiotherapy9, chemotherapy10, cytoreductive
41surgery11 and PDT12,13. MET is frequently expressed by cancer
42stem-like cells thought to drive tumour recurrence14, and abnormal
43MET signalling has been shown to promote the epithelial–mesench-
44ymal transition15, cancer cell stemness15 as well as tumour growth,
45invasion and metastasis5,15. Moreover, MET signalling is also
46observed in response to anti-VEGF therapy and comprises a promi-
47nent escape mechanism from antiangiogenic treatments5. When the
48tumour vasculature is pruned by anti-VEGF therapy, the hypoxic
49tumour microenvironment stimulates MET expression7,8,16.
50McDonald and colleagues elegantly demonstrated that concurrent
51inhibition of the VEGF and MET signalling pathways results in
52the favourable beneﬁts of antiangiogenic therapy in slowing
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1 tumour growth while mitigating the unwanted consequences of
2 increased intratumoural hypoxia—cancer cell migration and
3 tumour growth along remaining, functional vessels as well as via
4 lymphatic routes16,17. Here, we demonstrate that PDAC tumours
5 transiently upregulate MET signalling in response to PDT in vivo
6 (Supplementary Fig. 1), which closes the triangle to motivate a
7 three-way interactive therapy (Fig. 1b)—suggesting a compelling
8 rationale to combine concurrent anti-VEGF and -MET therapy
9 with PDT—and motivated development of the PMIL.
10 This approach—utilizing liposomes loaded with a lipophilic
11 therapeutic agent and encapsulating a PLGA nanoparticle that
12 releases a second, complementary agent—is supported by the reported
13 successes of nanoliposome-based delivery of chemotherapeutics18,19
14 (Supplementary Note 1). An advantage of this hybrid drug delivery
15 vehicle is that its lipid18 and polymer components20,21 are all in
16clinical use and are biodegradable, nontoxic chemicals that can be
17metabolized by the body. PMILs build on these advances by utiliz-
18ing light activation not only for photodynamic action but also as a
19drug release mechanism to enable tumour-focused, spatiotem-
20porally synchronized combination therapies. This opens the door
21to a number of combination therapies for which capturing and
22suppressing bursts in molecular signalling dynamics is key.
23PMIL design, synthesis and characterization
24PMILs were synthesized with the lipophilic photosensitizer BPD
25formulated within the lipid bilayer of a liposome encapsulating
26PLGA nanoparticles20,21 loaded with the hydrophobic multikinase
27inhibitor XL184 (Fig. 2a–c). The NP[XL184] was engineered to
28optimize the XL184 loading efﬁciency (Supplementary Fig. 2) and
29to be smaller in diameter than the liposomes (Fig. 2d,e) to facilitate
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Figure 1 | Concepts of spatiotemporal-synchronized combination therapy using PMILs. a, NIR light activates PMILs within the tumour microvasculature and
parenchyma for simultaneous neovascular damage, tumour cell apoptosis and necrosis as well as liposome disruption with initiation of sustained multikinase
inhibition. The PMIL delivery system is tuneable for simultaneous delivery of photodynamic, chemotherapeutics and small-molecular inhibitors. b, Schematic
of a three-way Q2interactive combination therapy with photodynamic tumour cell and microvasculature damage and inhibition of treatment escape pathways.
VEGFR signalling stimulates tumour angiogenesis and preparation of the premetastatic niche via supporting endothelial cell survival, migration and
proliferation as well as increased vessel permeability and chemotaxis of bone marrow derived progenitor cells. MET signalling promotes escape from
cytotoxic and antiangiogenic therapy via supporting cancer cell survival, motility and metastasis as well as cancer stem-like cell maintenance and tumour
angiogenesis via cross talk with the VEGFR pathway. XL184 inhibits activation of both the MET and VEGF signalling pathways to suppress tumour cell
survival, metastasis and regrowth following cytotoxic therapy.
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1 its encapsulation within the liposome. In this design, the lipid
2 bilayer acts to protect NP[XL184] from solvent exposure, limiting
3 hydrolysis and systemic XL184 release before photoinduced drug
4 release (Fig. 2f,g and Supplementary Fig. 3). We reasoned that
5 NIR irradiation (using a 690 nm laser matched to BPD absorption)
6 could deposit enough photonic energy to promote BPD-mediated
7 photochemistry at the lipid bilayer and disrupt the integrity of the
8 liposome4,22 (Supplementary Note 2), thereby exposing the NP
9[XL184] to solvents and accelerating the liberation of the payload
10in the target lesion (Fig. 2f). Reactive oxygen species scavengers sig-
11niﬁcantly suppressed photoinduced XL184 release indicating the
12involvement of photochemical drug release (Fig. 2f and
13Supplementary Fig. 4). The 50:50 PLGA ratio used to synthesize
14the NP[XL184] is designed for sustained XL184 delivery over a
15period of several days, with an initial burst release on liposome dis-
16ruption and water contact that is followed by a slower, sustained
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Figure 2 | Synthesis and characterization of a benzoporphyrin–XL184 PMIL. a, Diagrams of XL184-loaded nanoparticle (NP[XL184]) and BPD-loaded lipid
ﬁlm synthesis. b,c, Schematics and representative cryo-electron microscopy (cryo-EM) images of NP[XL184] (b) and PMIL (c). Arrows and arrowheads
indicate the outer lipid bilayer and an encapsulated nanoparticle, respectively, in c. Scale bars, 50 nm. d,e, Physical characterization of the various
nanoconstructs by dynamic light scattering (d) and nanoconstruct drug encapsulation efﬁciencies (e). Results are mean ± s.e.m. (NP[XL184] and PMIL,
n = 12 technical replicates each performed with an independent nanomaterial preparation; L[BPD], n = 10 technical replicates each performed with an
independent nanomaterial preparation). f, Photoinduced drug release from PMILs in serum versus release in the absence of laser irradiation. The arrows
indicate that a NIR light dose was given at the 5 h time point (37 °C; 100 mW cm−2; 5 J cm−2). Results are mean ± s.e.m. (n = 3 technical replicates each
performed with an independent nanomaterial preparation; error is small where not visible). Asterisks and hashes denote signiﬁcance compared with
untreated PMILs (PMIL, −hν) or NIR-irradiated PMILs (PMIL, hν) compared with NIR-irradiated PMILs in the presence of sodium azide (a reactive oxygen
species scavenger; PMIL, hν+Q), respectively (*,# P < 0.05, **,##P < 0.01, ***P < 0.001, one-way ANOVA with Tukey’s post hoc test). Trend lines are ﬁts to a
simple one- or two-phase exponential release model (see Methods). g, Schematic of PMIL ﬂuorescence imaging and photoinduced drug release. DOTAP,
1,2-dioleoyl-3-trimethylammonium-propane; DPPC, 1,2-dipalmitoly-sn-glycero-3-phosphocholine; DSPE-PEG, 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[methoxy(polyethylene glycol)200]; PLGA-PEG, poly-(lactic acid-co-glycolic) acid–polyethylene glycol conjugate.
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1 release phase due to nanoparticle erosion and XL184 diffusion
2 (Fig. 2f)20. In contrast, XL184 is released from the PMIL over a
3 period of several weeks in the absence of photoinduced release
4 (Fig. 2f). Electron microscopy indicates a NP[XL184] encapsulation
5 efﬁciency of ∼20% within liposomes (Fig. 3a–c and Supplementary
6 Fig. 5) and disruption of the bilayer following laser irradiation
7 (Fig. 3d,e and Supplementary Fig. 5). Surprisingly, although the
8 majority of NP[XL184] is unencapsulated by a lipid bilayer, light-
9 activated drug release is prominent and might be explained by the
10 self-assembly of lipid monolayers onto PLGA nanoparticles
11 (Supplementary Note 3).
12On photorelease, XL184 is liberated to initiate inhibition of
13multiple kinases (Supplementary Note 4). XL184 is approved by
14the US Food and Drug Administration for treatment of patients
15with medullary thyroid cancer, based on a promising phase III
16trial23, and is currently in clinical trials for PDAC (NCT01663272)
17as well as for a number of other malignancies. Because XL184
18inhibits escape from anti-VEGF therapy via MET signalling16 and
19inhibits pancreatic cancer stem-like cells14,24, XL184 offers
20promise for treatment of PDAC in comparison with the poor
21phase III results for anti-VEGF therapy alone in combination
22with gemcitabine25.
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Figure 3 | Structural imaging of NP[XL184] encapsulation and XL184 photorelease from PMILs. a, Representative cryo-EM images of NP[XL184], L[BPD]
and PMIL. b, Cryo-EM tomogram of a PMIL. Arrows and arrowheads in a and b indicate the outer lipid bilayer and encapsulated nanoparticles, respectively.
Scale bars, 50 nm. Empty liposomes, unencapsulated NP[XL184] and multilamellar liposomes were also observed in the PMIL samples (Supplementary
Fig. 5a–c and Supplementary Note 3). c, 3D renders of an example PMIL encapsulating a nanoparticle as Q3well as an example of an unencapsulated
nanoparticle from a cryo-EM tomogram of a PMIL sample. The dashed circles indicate the rendered objects in the lower 2D tomogram slice. d,
Representative transmission electron microscopy (TEM) images of NP[XL184] and PMIL treated with varying NIR light doses (100 mW cm−2; 0, 5, 50, or
100 J cm−2), and using negative staining with phosphotungstic acid. Arrows and arrowheads indicate intact liposomes and unencapsulated nanoparticles,
respectively. Scale bars, 100 nm. e, Quantiﬁcation of intact liposomes and unencapsulated nanoparticles shown in (d) (Supplementary Fig. 5e). Results are
mean ± s.e.m. Asterisks in (e) denote signiﬁcance compared with untreated PMILs, 0 J cm−2 (PMIL 0 J cm−2, n = 14 images; PMIL 5 J cm−2, n = 5 images;
PMIL 50 J cm−2, n = 10 images; PMIL 100 J cm−2, n = 5 images; the images were collected from two technical replicates performed with a single nanomaterial
preparation for each group; **P < 0.01, ***P <0.001, Kruskal–Wallis one-way ANOVA).
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1 In addition to photorelease of NP[XL184], NIR irradiation also
2 triggers BPD-PDT to directly damage microvasculature, cancer
3 cells or both, depending on the time of illumination following
4 BPD administration26–28. As an example, BPD-PDT is used routi-
5 nely in the clinic for selective closure of choroidal neovasculature
6 associated with age-related macular degeneration while sparing
7 the overlying neurosensory retina to preserve visual acuity29. For
8 oncological applications, BPD-PDT is often most effective at time
9 points that balance BPD localization in neovasculature with extrava-
10 sation into the tumour parenchyma (60–90 min post-injection),
11 which induces both microvasculature and cancer cell destruction26.
12 In a promising phase I/II clinical trial (VERTPAC), such a BPD-
13 PDT regimen produced a 1–4 cm zone of tumour necrosis with a
14 100% patient response rate for light delivered via optical ﬁbers posi-
15 tioned percutaneously within locally advanced PDAC tumours
16 under computed tomography guidance30. Moreover, the unique
17 mechanisms of cell death induced by PDT31,32—including direct
18 damage to Bcl-2 protein (a major anti-apoptotic factor and mediator
19 of drug-resistance) and mitochondrial cytochrome c release (a potent
20 pro-apoptotic signal)—are effective against chemo- and radio-
21 resistant cells33–35 and sensitize cancer cells to chemotherapeutics33,34
22 as well as to molecular inhibitors12,36.
23 BPD is nontoxic (Supplementary Note 5), however, XL184 pos-
24 sesses signiﬁcant toxicities that can require concomitant medi-
25 cations, dose interruption or dose reduction23. To limit the need
26 for chronic XL184 administration and its systemic exposure to the
27 body, the PMIL was designed to realize tumour-focused release of
28 XL184.
29 Cellular PMIL internalization and in vitro efﬁcacy
30 Cellular uptake of PMILs and of liposomes loaded with BPD in the
31 bilayer but lacking XL184, L[BPD], was determined by BPD ﬂuor-
32 escence confocal microscopy in monolayer cultures of AsPC1 cells
33 derived from metastatic human PDAC ascites (VEGR1+ and
34 MET+ with multiple oncogenic mutations; Supplementary Note
35 6). Both the PMIL and the L[BPD] underwent cellular internaliz-
36 ation (Fig. 4a), with similarity to the pharmaceutical formulation
37 of BPD35. BPD-PDT of AsPC1 cells using either L[BPD] or
38 PMILs results in increased MET activation (Fig. 4b,c and
39 Supplementary Fig. 6). PDT-induced MET activation is downregu-
40 lated using scavengers of reactive oxygen species produced by PDT
41 photochemistry or by inhibiting epidermal growth factor receptor
42 (EGFR)-mediated transactivation of MET (Fig. 4b and
43 Supplementary Note 7). To investigate MET inhibition on PMIL
44 uptake into cancer cells, and photoinduced release of XL184,
45 western blotting was used to measure phosphorylated MET
46 (pMET; activated MET) as well as total MET expression for
47 untreated AsPC1 cells versus cells treated with L[BPD] or PMILs
48 that received a sub-lethal dose of NIR light (1 J cm−2) after a 1 h
49 incubation period (Fig. 4c). BPD-PDT using L[BPD] results in
50 enhanced MET phosphorylation while PMILs suppress MET acti-
51 vation (Fig. 4c). In the absence of photoinduced XL184 release,
52 the PMILs have no effect on the basal pMET level (Fig. 4c). These
53 results indicate that NIR irradiation triggers XL184 release from
54 the PMIL such that the initiation of MET inhibition coincides
55 with photodynamic cytotoxicity. Note that in contrast to photoin-
56 duced suppression of MET activation, none of the treatment arms
57 had a signiﬁcant impact on the total MET level.
58 Harnessing this photoinduced release of XL184 from PMILs, we
59 hypothesized that simultaneous photocytotoxicity and inhibition of
60 MET activation—and, thereby, suppression of downstream anti-
61 apoptotic survival pathways14—could enhance cancer cell death.
62 Note that XL184 also inhibits other receptor tyrosine kinases
63 involved in intra- and autocrine cancer cell signalling, such as
64 VEGFR1 (Supplementary Note 4). Cancer cell death was probed
65 for the following treatments (250 nM BPD and/or 100–125 nM
66XL184) administered to AsPC1 cells: XL184; NP[XL184]; L[BPD];
67co-administration of L[BPD] and NP[XL184] as separate agents;
68and PMIL. The submicromolar doses of XL184 used here do not
69induce cancer cell death as a single agent (Fig. 4d and
70Supplementary Note 8). NIR photoirradiation (690 nm) was per-
71formed for a range of light doses (0–10 J cm−2) 1 h post drug
72administration. L[BPD]- and PMIL-PDT showed a characteristic
73increase in cell killing with increasing light dose with no dark tox-
74icity. Furthermore, MET inhibition using PMILs induces an
75enhanced level of cancer cell death in comparison with L[BPD]-PDT
76as well as in comparison with co-administration of L[BPD] and
77NP[XL184] as separate agents (Fig. 4d). Collectively, these in vitro
78cancer cell culture studies indicate that inhibition of kinase acti-
79vation simultaneous with photocytotoxicity can enhance cancer
80cell death.
81PMIL efﬁcacy in two mouse models of pancreatic cancer
82The suppression of MET activation and modest enhancement of
83cancer cell cytotoxicity using the PMIL in vitro is promising for
84in vivo application. In vivo, the PMIL acts not only on cancer cells
85but also on paracrine receptor tyrosine kinase signalling, the
86tumour vasculature, tumour cell motility and metastatic escape,
87with potential to provide further gains in efﬁcacy compared with
88conventional drug formulations. For instance, XL184 acts on endo-
89thelial cells lining tumour blood16 and lymphatic17 vessels (via
90VEGFR inhibition, for example). To assess the efﬁcacy of PMILs
91in controlling localized tumours in vivo, we performed a single treat-
92ment cycle in established xenograft tumours (∼50 mm3 in size) 18 d
93following subcutaneous implantation of AsPC1 cells in mice. A
94single intravenous administration of the following treatments was
95given to the randomized mice: no-treatment control; XL184;
96NP[XL184]; L[BPD]; co-administration of L[BPD] and NP[XL184]
97as separate agents; and PMIL. Each formulation contained 0.25
98mg kg−1 of BPD and/or 0.1–0.125 mg kg−1 XL184. Here, NIR
99irradiation was performed 1 h following injection—via transcu-
100taneous illumination of the tumour—to induce both vascular and
101cancer cell destruction. In contrast to the continued tumour
102growth observed for XL184 and BPD-PDT monotherapy, the
103PMIL-mediated combination therapy exhibited a prolonged
104reduction in tumour volume over 10 d following a single treatment
105(Fig. 5a). Compared with the no-treatment control group, the mean
106tumour reduction following PMIL treatment was 92% (day 37;
107Fig. 5b). This result contrasts with the monotherapy controls and
108the combination therapy by conventional co-administration of
109L[BPD] and NP[XL184] as separate agents—all of which showed
110marginal anti-tumour effects as a trend in slowing tumour growth
111but did not achieve a signiﬁcant reduction in tumour volume
112(Fig. 5a,b).
113To investigate toxicity, metastasis and microvascular effects, and
114to further probe local tumour control in a another tumour model
115using PMILs, we next investigated the same treatment arms in a
116metastatic mouse model by implanting PDAC cells into the pan-
117creas. Mouse weight was monitored before (day 10 post-tumour
118inoculation) and after (day 24) treatment as a metric of toxicity
119(Fig. 5c). The gain in mouse weight and 100% survival of the
120mice through the treatment endpoint (day 24) indicate that PDT
121combined with low-dose XL184 treatment has low toxicity
122(Fig. 5c). Furthermore, pancreatic tumour volumes and histopathology
123(Supplementary Fig. 8) assessed at the treatment endpoint (day 24)
124corroborate the enhanced local control of the primary tumour, as
125found in the subcutaneous model for PMILs (Fig. 5d).
126These orthotopic pancreatic tumours are hypovascular in com-
127parison with the surrounding pancreatic tissue (Fig. 6a,b).
128Nevertheless, XL184 (P = 0.19, Mann-Whitney U test) and PMIL-
129treatment (P = 0.20, Mann-Whitney U test) selectively induced
130trends in reduced intratumoural—but not peritumoural—microvessel
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Figure 4 | MET inhibition enhancement of PDT-induced cancer cell death in vitro using PMILs. a, Representative confocal BPD ﬂuorescence (red)
microscopy images and quantiﬁcation of BPD ﬂuorescence during L[BPD] and PMIL cellular uptake in monolayer AsPC1 cell cultures (no light irradiation for
therapy). The image at 0 min represents the minimal live cell autoﬂuorescence before adding L[BPD] or PMIL, and later time points demonstrate increasing
cellular accumulation of BPD resulting from nanoconstruct internalization. Results are mean ± s.e.m. (n = 3 biological replicates per condition × 3 images per
replicate). Trend lines are ﬁts to a simple pharmacokinetic model (Methods). b, Western blotting and quantiﬁcation of total MET and pMET expression—
normalized to β-actin and relative to the no-treatment control group (normalized to 1)—indicate that pMET increases 24 h following PDT with L[BPD]
(L[BPD]-PDT; 125 nM BPD; 690 nm; 100 mW cm−2; 2.5 J cm−2), whereas there is no signiﬁcant change in overall MET protein expression following PDT
over a range of PDT doses (Supplementary Fig. 6). A singlet oxygen-speciﬁc scavenger (Singlet Oxygen Sensor Green, SOSG; 100 μM) inhibits L[BPD]-PDT
activation of MET signalling, whereas a free radical scavenger (mannitol, 50 mM) has only a modest affect. In addition, an EGFR-speciﬁc kinase inhibitor,
AG1478 (12.5 nM), also inhibits MET activation following PDT whereas toxin B (2 ng ml–1), an inhibitor of GPCR-mediated MET transactivation, has no effect.
Results are mean ± s.e.m. Underlined asterisks denote signiﬁcance compared with no treatment, and the remaining asterisks denote signiﬁcance compared
with L[BPD]-PDT, L[BPD] (hν), or amongst the indicated groups (n = 3 biological replicates per condition; ***P < 0.001, ****P < 0.0001, one-way ANOVA
with Tukey’s post hoc test). c, Western blots and quantiﬁcation of photoinduced suppression of MET activation (pMET) using PMILs 24 h following
treatment. In contrast to increased pMET following L[BPD]-PDT, MET activation is suppressed following PDT with PMILs (250 nM BPD; 690 nm; 100 mW
cm−2; 1 J cm−2). Without photoinduced XL184 release (PMIL, −hν), the PMIL has no effect on the basal levels of pMET. Results are mean ± s.e.m. (n = 2
biological replicates per condition; **P < 0.01, ***P < 0.001, one-way ANOVA with Tukey’s post hoc test). d, MTT assay of AsPC1 cell viability following XL184
and PDT monotherapy or combination therapy. Results are mean ± s.e.m. Asterisks denote signiﬁcance compared with no treatment or amongst the
indicated groups (No-treatment control and L[BPD] 0 J cm−2, n = 17 biological replicates; XL184, n = 10 biological replicates; NP[XL184], n = 16 biological
replicates; L[BPD] +NP[XL184] 0 and 1 J cm−2, n = 5 biological replicates; L[BPD] 1 J cm−2, L[BPD] +NP[XL184] 2.5, 5 and 10 J cm−2, PMIL 0 and 1 J cm−2,
n = 8 biological replicates; L[BPD] 2.5, 5 and 10 J cm−2, and PMIL 2.5, 5 and 10 J cm−2, n = 11 biological replicates; *P <0.05, **P <0.01, ***P < 0.001, one-way
ANOVA with Tukey’s post hoc test). Fisher’s least signiﬁcant difference post hoc test of the integrated PDT dose response curves (analysis of the area under
the curve mean and standard error) indicates that the PMIL achieves enhanced cancer cell death versus L[BPD] +NP[XL184] (P <0.05) and L[BPD]
(P <0.001) (Supplementary Fig. 7a).
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1 density versus the no-treatment control tumours (Fig. 6b). Because
2 of the substantial degree of tumour shrinkage by PMILs (Fig. 5d),
3 which tends to compact the remaining vasculature and to obscure
4 interpretation of microvessel density37, we also estimated the intra-
5 tumoural microvessel volume using an immunoﬂuorescence and
6 digital slide scanning microscopy technique to efﬁciently sample
7 the endothelial cell content of entire tumour volumes38 (see
8 Methods and Supplementary Note 9). The intratumoural microves-
9 sel volume estimate revealed a signiﬁcant reduction in total tumour
10 microvascularity achieved by the PMIL, which suggests an antivas-
11 cular effect facilitated by PDT with suppression of vascular and
12 tumour regrowth by sustained XL184 release. Furthermore, invasive
13 tumour borders and metastatic inﬁltrates within the surrounding
14 pancreatic tissue characterize this orthotopic model of PDAC
15 (Fig. 6a). Metastases in the liver and retroperitoneal lymph nodes
16 appear rapidly in this model, as assessed by a quantitative polymer-
17 ase chain reaction assay (Methods) that measures the number of
18 viable human metastatic cancer cells in organ biopsies (Fig. 6d).
19 The single PMIL treatment achieved a 98.7% mean reduction in
20 liver and retroperitoneal lymph node metastasis compared with
21the no-treatment control group at the treatment endpoint (day
2224), while the other treatment groups did not achieve a statistically
23signiﬁcant change in metastasis (Fig. 6d).
24The local tumour reduction and suppression of metastasis result-
25ing from a single PMIL treatment contrasts with the use of XL184 as
26a single agent, which is given daily over an extended period by oral
27administration. For instance, 99% primary tumour reduction, 79%
28microvessel density reduction and 100% liver metastasis reduction
29were reported in a mouse model of pancreatic neuroendocrine
30tumours (40 mg kg−1 XL184, administered daily for 3 weeks)16.
31Here, a single PMIL treatment (including 0.1–0.125 mg kg−1
32XL184) achieved 92 and 61% reductions of subcutaneous and
33orthotopic PDAC tumours, respectively, with 70% intratumoural
34microvessel volume reduction and 99% metastatic cancer cell
35reduction in the liver and regional lymph nodes. Remarkably, the
36interaction of PDT with photoinitiated and sustained XL184
37release facilitated by the PMIL enables the same therapeutic efﬁcacy
38of daily oral XL184 monotherapy with less than a thousandth
39(∼1/6,700) of the XL184 dosage (Supplementary Note 10). This
40indicates that the PMILs offer a signiﬁcant potential to reduce
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Figure 5 | Prolonged tumour reduction in vivo with a single cycle of PMIL-treatment. a,b, Combined BPD-PDT (690 nm; 100 mW cm−2; 75 J cm−2) and
XL184 treatment using PMILs achieves prolonged reductions in subcutaneous tumour volumes (a) with a minimal fractional residual tumour on day 37 (b).
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inoculation). Results are mean ± s.e.m. Asterisks denote signiﬁcance compared with no treatment or amongst the indicated groups (n = 16 mice per group;
*P <0.05, **P <0.01, ***P <0.001, Kruskal–Wallis one-way ANOVA). A single cycle of combination therapy using PMILs achieves enhanced reductions in
orthotopic tumours (P =0.011, two-way ANOVA BPD-PDT·XL184 interaction term; Supplementary Fig. 7b and Supplementary Tables 1 and 2)—but not using
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1 systemic exposure to XL184, reducing the risks of toxic side effects
2 and the need for dose interruptions.
3 The in vivo efﬁcacy of PMIL also contrasts strongly with co-
4 administration of L[BPD] and NP[XL184] as separate agents. The
5 PMIL unites the pharmacokinetics of L[BPD] and NP[XL184]
6 delivery and enables tumour-conﬁned, photoinduced XL184
7 release, while the conventional delivery of L[BPD] and
8 NP[XL184] precludes a full interaction between these therapies.
9 The enhanced efﬁcacy of the PMIL highlights the importance of
10 co-packaging interactive therapeutic agents into one carrier with
11 spatiotemporally synchronized release. Note that although XL184
12 had no cytotoxicity as a single agent in vitro (Fig. 4d), PMIL treat-
13 ment achieved super-additive cancer cell killing both in vitro and
14 in vivo (Supplementary Fig. 7), which suggests a synergistic inter-
15 action between XL184 and BPD-PDT facilitated by the PMIL
16 (Supplementary Note 11). The requirement for co-packaging to
17 achieve maximal impact is probably due to rapid (within 1–4 h)
18 microvessel damage and shutdown by both XL18439 and BPD27
19 that mutually compromise co-delivery of these therapies as separate
20 agents using conventional drug delivery formulations. The rapid
21 vascular effects of PDT in particular (<1 h for blood ﬂow stasis
22 onset with a duration > 48 h27) would preclude XL184 delivery
23 during the critical time window for anti-apoptotic signalling and
24 vascular regrowth inhibition during the burst in tumour VEGF
25(within 6 h40) and MET (within 72 h; Supplementary Fig. 1) signal-
26ling that follows cytotoxic therapy. Rapid PDT-induced vascular
27shutdown would inhibit overall XL184 delivery (55 h half-life)
28whereas nanoparticles entrapped in the tumour release XL184
29locally for a sustained period to inhibit vascular regrowth and
30metastasis following PDT. XL184 could be administered before
31PDT but this still precludes sustained therapeutic doses of XL184
32until tumour vascular regrowth following PDT.
33Conclusions
34In summary, the complexities of cancer necessitate the innovation
35of drug delivery platforms that are capable of addressing multiple
36tumour compartments as well as treatment escape mechanisms.
37An emerging paradigm in cancer therapy suggests that gains in
38local tumour control can be compromised by co-activation of mul-
39tiple tumour survival signalling pathways that promote increased
40invasiveness and metastasis5,8. This aggressive response to treatment
41may ultimately limit patient survival. Combination therapies hold
42great promise for overcoming this paradox by addressing the mech-
43anisms of tumour recurrence and treatment escape. However, co-
44activation of multiple tumour survival signalling pathways and
45microvessel shutdown limit the efﬁcacy of sequential drug delivery.
46New drug delivery systems are needed to facilitate combinations that
47span cytotoxic, antivascular and anti-invasive mechanisms. To
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Figure 6 | Antivascular and antimetastatic effects using a single PMIL-treatment cycle in vivo. a, A representative confocal ﬂuorescence image mosaic of
an entire orthotopic PDAC tumour cross-section with 1.2 μm x–y sampling illustrates selective immunostaining of human epithelial cancer cells (green) to
discriminate intra- (red) and peritumoural (gray scale) endothelial cells. Arrows indicate local metastases and cancer cells inﬁltrating the surrounding
pancreatic tissue. Scale bar, 1 mm. b, Intra- and peritumoural microvessel densities at the treatment endpoint. c, A single PMIL treatment induces a decrease
in intratumoural microvessel volume. Results are mean ± s.e.m. Asterisks denote signiﬁcance compared with no treatment or amongst the indicated groups
(no-treatment control, n = 8 entire tumour cross-section image mosaics from 8 mice; XL184, n = 7 entire cross-sections from 3 mice; NP[XL184], n = 8 entire
cross-sections from 4 mice; L[BPD], 8 entire cross-sections from 4 mice; L[BPD] +NP[XL184], 10 entire cross-sections from 5 mice; PMIL, 10 entire cross-
sections from 7 mice; **P < 0.01, Kruskal–Wallis one-way ANOVA). d, A single PMIL treatment reduces the number of total number of metastatic cancer
cells in the liver and regional lymph nodes. Results are mean ± s.e.m. Asterisks denote signiﬁcance compared with no treatment (no-treatment control,
NP[XL184], L[BPD] +NP[XL184], and PMIL, n = 20 mice per group; XL184, n = 18 mice; L[BPD], n = 16 mice; *P < 0.05, Kruskal–Wallis one-way ANOVA).
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1 address these challenges, we developed PMILs that integrate the
2 antivascular and antiangiogenic mechanisms of photodynamic
3 and anti-VEGF therapy while blocking tumour cell invasion, metas-
4 tasis and escape via the MET pathway. This approach is inspired by
5 recent advances in photoactivated nanomaterials2,4, multi-drug
6 loaded41 as well as stimuli-responsive liposomes42 and by the nano-
7 cell platform43, which introduced extrinsically activated drug
8 release, maintenance of synergistic drug ratios and temporal target-
9 ing of distinct tumour compartments, respectively. PMILs utilize
10 these features for multi-agent co-delivery with photorelease and
11 entrapment of NP[XL184] within the tumour following vascular
12 shutdown for sustained release. This approach uniquely enables a
13 tumour-conﬁned, spatiotemporally synchronized multi-modal
14 combination therapy at the ‘right time and right place’. The PMIL
15 attenuates metastatic outgrowth and escape but the photodynamic
16 component is limited at present to localized tumours and further
17 developments will be needed to address established distal metas-
18 tases. Note that XL184 is eventually released from the PMIL in
19 the dark (Fig. 2f) such that established metastases will be impacted
20 by passive tumour accumulation of PMILs via the enhanced per-
21 meability and retention effect.
22 Future work will address models of advanced metastatic disease
23 and will potentially involve further developments to incorporate tar-
24 geted and activable delivery for wide-ﬁeld PDT with sufﬁcient selec-
25 tivity to treat disseminated micrometastases44. The role of the
26 unencapsulated NP[XL184] population, and the possibility of a
27 BPD-loaded lipid monolayer that contributes to light-activated
28 therapy, will also be the subject of future studies. Alternatively, it
29 is possible that the encapsulated NP[XL184] is the dominant contri-
30 butor such that further reduction in the XL184 dose and systemic
31 toxicity may be achieved by puriﬁcation of the encapsulated
32 NP[XL184]. Collectively, the present study demonstrates that
33 PMILs maximize therapeutic efﬁcacy per treatment cycle and
34 further studies are warranted to investigate the long-term impacts
35 on cure rate, survival and potentiation of standard chemotherapy
36 regimens. The continuing phase II/III studies of PDT in PDAC
37 form a good basis for developing this approach further.
38 Methods
39 Methods and any associated references are available in the online
40 version of the paper.
41 Received 31 October 2015; accepted 27 November 2015;
42 published online XX XX 2016
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Q7 1 Methods
2 NP[XL184] synthesis and characterization. Before NP[XL184] synthesis, the
3 biodegradable copolymer PLGA 50:50 (17 kDa; 0.18 dL g−1; Lake Shore
4 Biomaterials) was modiﬁed to incorporate a PEG moiety (COOH-PEG-NH2;
5 3.5 kDa; JenKem Technology), which enhances both nanoparticle stability and
6 circulation time18. Synthesis was then performed by nanoprecipitation45. To achieve
7 maximal XL184 loading, nanoparticles were synthesized with various XL184
8 (>99.0% purity; Selleck Chemicals) and PEG-PLGA drug/polymer ratios ranging
9 from 1–10% (w/w). Of the tested ratios, the XL184 molar loading efﬁciency was
10 maximal at a drug/polymer (w/w) ratio of 1% (Supplementary Fig. 2). In addition, a
11 range of solvent:water ratios (1:2–1:10) were tested and the optimal ratio for
12 NP[XL184] formation was 1:3 acetone:water. For the optimized synthesis protocol,
13 XL184 was co-solubilized in 1 ml of acetone with PLGA-PEG at a 1% (w/w) drug to
14 polymer concentration. Nanoprecipitation was achieved by adding this mixture
15 dropwise using a 27.5-gauge needle to 3 ml of H2O stirred magnetically at 400 rpm.
16 The reaction mixture was then stirred uncovered for 6 h to allow acetone
17 evaporation, passed through a 0.2 µm ﬁlter and puriﬁed by ultraﬁltration (Amicon-
18 Millipore; 30 kDa cut-off ) at 2,500 rpm for 10 min with intermittent washing
19 (4 cycles; 4 ml phosphate-buffered saline per wash). The XL184–PLGA nanoparticle
20 loading efﬁciency was determined by optical absorption measurements following
21 solvation of the nanoparticles in dimethyl sulfoxide, using the formula: 100·(no. of
22 moles following puriﬁcation/no. of moles available for synthesis). All NP[XL184]
23 size and charge measurements were made by dynamic light scattering (Malvern,
24 Zetasizer Nano ZS).
25 PMIL synthesis and characterization. PMILs co-encapsulating BPD (verteporﬁn;
26 VWR International) and NP[XL184] were prepared by modiﬁcation of existing
27 synthesis methods43. The lipids (DPPC, DOTAP, cholesterol, and DSPE-PEG;
28 Avanti Polar Lipids) were each dissolved separately in chloroform, and then mixed
29 together in a molar ratio of 2:0.2:1:0.2 (DPPC:DOTAP:cholesterol:DSPE-PEG) with
30 100 nmoles of BPD. This lipid composition was selected on the basis of the
31 previously reported pharmacological success of similar compositions18. Inclusion of
32 the cationic lipid, DOTAP, resulted in a zeta potential (surface charge) of +3 mV.
33 This slightly cationic surface charge promotes cellular uptake without signiﬁcant
34 cytotoxicity to maintain biocompatibility46. To form thin lipid ﬁlms containing
35 BPD, chloroform was removed by rotoevaporation and by placing the sample under
36 vacuum overnight. Next, lipid ﬁlm hydration was achieved by adding NP[XL184]
37 (50 nmoles of XL184) in 1 ml of phosphate-buffered saline. To ensure adequate
38 encapsulation of NP[XL184], the thin ﬁlm was subjected to 10 freeze-thaw cycles
39 (6 min per cycle)Q5 at 0 and 45 °C, below and above the highest transition temperature
40 of the lipid mixture (DPPC; Tm = 41 °C). The resulting dispersion of multilamellar
41 liposomes was extruded through a 200 nm diameter polycarbonate membrane using
42 a mini-extruder system (Avanti Polar Lipids) to form unilamellar liposomes. BPD
43 and XL184 not loaded into the PMIL were removed by dialysis (Spectra/Por;
44 300 kDa cutoff; 1 ml sample in 4 l of phosphate-buffered saline at 4 °C for 18 h).
45 During the dialysis period, the sample was analysed by dynamic light scattering
46 measurements. Initially, these measurements indicated a bimodal distribution with
47 peaks at 80 nm (NP[XL184]) and 150 nm (PMIL), which gradually became a single
48 monodispersive peak (PDI < 0.2) as puriﬁcation of the PMILs completed. However,
49 electron microscopy revealed the presence of residual NP[XL184] not incorporated
50 within liposomes within the PMIL samples (Supplementary Note 3). The PMIL
51 BPD and XL184 concentrations and loading efﬁciencies were determined by
52 ﬂuorescence and absorbance spectroscopy or by high-performance liquid
53 chromatography (Hydrosil C18 ODS; 2.0 × 14.0 cm; 50% acetonitrile in H2O→ 100%
54 acetonitrile; 0.5 h), respectively, following solvation of the PMILs in dimethyl
55 sulphoxide. All PMIL size and charge measurements were made by dynamic light
56 scattering (Malvern, Zetasizer Nano ZS). L[BPD] was synthesized analogously to the
57 PMIL, but without NP[XL184].
58 PMIL stability and drug photorelease kinetics. PMIL and NP[XL184] size stability
59 during storage at 4 °C was investigated by repeated dynamic light scattering
60 measurements over a period of 40 d (Supplementary Fig. 3). Dark release and
61 photoinduced drug release were measured using dialysis membranes in phosphate-
62 buffered saline at 37 °C with 10% fetal bovine serum added to each dialysis tube
63 (Spectra/Por; NP[XL184], 100 kDa cutoff; PMILs, 300 kDa cut-off; Fig. 2f ). A 690
64 nm diode laser (High Power Devices, Inc.) was used for all NIR irradiation
65 experiments. During dialysis samples were collected periodically and placed
66 immediately in acetonitrile containing 1% of the internal standard N-(1-naphthyl)
67 ethylenediamine. Separation and quantiﬁcation of drug components was achieved
68 by liquid chromatography-tandem mass spectrometry (LC-MS/MS) using standard
69 curves for each drug normalized to the internal standard. Brieﬂy, 1.0 µl of dialysis
70 sample was injected into a ZorbaxC18 (2.1 × 50 mm) column eluted at 0.400 ml
71 min–1 with acetonitrile and 10 mM ammonium formate (80% → 20% over 4 min).
72 Detection of drug components was made using triple quadrupole MS/MS detection
73 with an ion source ESI+ in MRM scan mode to identify the product ions for BPD
74 (ret. time = 4.12 min, 513 m/z) and XL184 (ret. time = 2.68 min, 232 m/z).
75 Quantitative analysis of chromatograms allowed for area under curve integrations of
76 each product ion normalized to the internal standard (ret. time 1.20 min; 170 m/z).
77 Total moles were determined using standard curves and percent loss calculated for
78each time point after correcting for sample volume changes. The resulting BPD and
79XL184 release proﬁles were ﬁt individually to a simple one- or two-phase
80exponential model: a0 + a1 · e
−k1·t + a2 · e
−k2·t, Q6where a0 is an offset, a1 and a2 are the
81maxima release plateaus (at equilibrium) of phases 1 and 2, k1 and k2 are the release
82rate constants of phases 1 and 2, and t is time from placing the sample in serum
83media within the dialysis tube. Note that XL184 release from NP[XL184] is
84sufﬁciently described by a single-phase model (P=0.067, two-phase alternative
85hypothesis), whereas XL184 release from the PMIL with or without laser irradiation
86is best described by the multi-phase model (P =0.0003–0.0079). Dynamic light
87scattering and transmission electron microscopy were also performed before and
88after photoirradiation (Fig. 3 and Supplementary Fig. 4).
89Cryo-electron microscopy. Cryo-EM was performed using a FEI Technai G2 Polara
90microscope equipped with an energy ﬁlter (Gatan) and a K2 Summit direct
91detection device (Gatan). Brieﬂy, 5 µl of nanomaterial sample (∼60 µM BPD for the
92PMIL or L[BPD]; ∼30 or 125 µM XL184 for the PMIL or NP[XL184], respectively)
93mixed with 2 µl of BSA Gold Tracer (EM-grade 6 nm; Electron Microscopy Sciences,
9425484) re-suspended in phosphate-buffered saline were deposited onto glow-
95discharged holey carbon grids (QUANTIFOIL R 2/1 200 mesh, copper; Electron
96Microscopy Sciences), blotted and rapidly vitriﬁed in a liquid ethane and propane
97mixture (50:50) using a custom-built plunger (Max Planck Institute of Biochemistry,
98Germany). Imaging was performed at 300 kV under low-dose conditions with 4.98
99or 6.12 Å sampling and a defocus of −3 or −6 µm for 2D or 3D images, respectively.
1002D images were obtained using the dose-fractionation mode of the detector
101(∼20–40 e/Å2 cumulative dose). Tilt series (±60°) for tomography were collected
102around a single axis with a 2° sampling increment using SerialEM software47
103(∼100 e/Å2 cumulative dose). Tomographic reconstructions were calculated using
104the IMOD tomography package48. Renders of 3D PMIL and NP[XL184] objects
105were created by manual segmentation in IMOD and rendered using VMD49.
106Manual particle counting was performed as described in Supplementary Fig. 5.
107Only unambiguous NP[XL184] objects were counted (∼20 nm in diameter or
108greater). Mean lamellarity was calculated as:
∑
L (NL · L)/
∑
L NL, where NL is the
109number of objects with lamellarity L (for example, L = 1 for unilamellar liposomes).
110Transmission electron microscopy. TEM (Philips CM10) was performed using
111negative staining either on untreated (200 mesh nickel PELCO Support Film with a
112Formvar/carbon coating, Ted Pella Inc.) or ionized carbon coated grids (to promote
113sample adhesion). Brieﬂy, 10 µl of the sample was added to the grid, air-dried and
114stained (2 µl, 1.0% phosphotungstic acid). Next, the grid was blotted dry and washed
115with 5 µl of dH2O. Imaging was performed at 100.0 kV and magniﬁcations of
116∼10,000–50,000×.
117Cell culture studies. Monolayer cultures of AsPC1 cells (American Type Culture
118Collection, CRL-1682; low passage number, <20)—recently tested (July 2015) and
119found to be negative for mycoplasma contamination (MycoAlert mycoplasma
120detection kit, Lonza)—were maintained in media (RPMI 1640, Mediatech)
121supplemented with 10% fetal bovine serum (Invitrogen), 100 units per ml penicillin
122and 100 µg per ml streptomycin. The AsPC1 cell line has not been listed in the
123database of cross-contaminated or misidentiﬁed cell lines maintained by the
124International Cell Line Authentication Committee. Cellular uptake of PMILs and
125L[BPD] was tested in multi-well plates with coverslip bottoms (Greiner Bio-One)
126plated with AsPC1 cells allowed to attach and grow overnight. Nanoconstructs were
127added to the wells at staggered time points to reach a concentration of 100 nM BPD
128and to achieve varying incubation times at 37 °C (15–90 min). Imaging was
129performed with an Olympus FV1000 confocal microscope with a 20 × 0.75 NA
130(numerical aperture) objective. BPD excitation was performed using a 405 nm diode
131laser with an emission spectrograph centred on the 696 nm BPD ﬂuorescence
132emission peak. The laser, photomultiplier tube detector and pinhole settings, as well
133as brightness–contrast adjustment settings for display, were kept constant for all
134images. In addition, phase contrast images were collected during microscopy to
135focus on a high-density ﬁeld of cells (not shown). Images were also collected for
136untreated cells (0 min) to quantify the autoﬂuorescence background and to deﬁne a
137ﬂuorescence intensity threshold that rejects 99.5% of the background signal. This
138intensity threshold was applied to all images to select pixels above the
139autoﬂuorescence background (true BPD signal) for analysis. The resulting cellular
140uptake data was ﬁt to a simple biexponential pharmacokinetic model: a · (e−k·t − e−j·t),
141where k and j are the elimination and absorption rate constants, a is a coefﬁcient
142dependent on the administered BPD dose as well as its bioavailability and t is time
143post-administration. For in vitro PDT, 0.25·106 AsPC1 cells were grown on a 35-mm
144culture dish for 24 h and incubated with nanoconstructs containing BPD (250 nM
145equivalent) and/or XL184 (100–125 nM equivalent) in 1 ml complete medium for 1 h.
146The incubation media was then replaced with 2 ml of fresh, complete media before
147photoirradiation. This removal of nanoconstructs not uptaken by cells before
148irradiation limits the release of XL184 and the generation of photocytotoxic species
149to intracellular and cell-associated nanoconstructs. Cell viability was measured using
150the MTT assay 24 h following light irradiation. Singlet Oxygen Sensor Green
151(SOSG; Molecular Probes) and D-mannitol (Sigma-Aldrich) were used to probe
152reactive oxygen species involvement in BPD-PDT-induce MET activation.
153Tyrphostin AG1478 (Sigma-Aldrich) and bacterial toxin B (Toxin B, Clostridium
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1 difﬁcile - Calbiochem, Millipore) were used to test for the involvement of enzymes
2 known to participate in MET transactivation. SOSG and mannitol were added to
3 cells immediately before laser irradiation in fresh media and then removed
4 immediately after PDT by a second media replacement step. AG1478 and toxin B
5 were incubated with cells in fresh media for 30 min and 2 h, respectively, before laser
6 irradiation and then removed immediately after PDT by a second
7 media replacement.
8 In vivo mouse models and treatments. All animal experiments were conducted
9 with approval and according to guidelines established by the Massachusetts General
10 Hospital Institutional Animal Care and Use Committee. Experiments were carried
11 out on 6-week-old male Swiss nude mice weighing 20–25 grams (Cox Breeding
12 Laboratories). For tumour implantations and photoirradiation, animals were
13 anesthetized with 84 mg kg−1 ketamine and 12 mg kg−1 xylazine. Tumours were
14 implanted by injection of a 50 µl volume containing 106 AsPC1 cells in a 1:1 mixture
15 of Matrigel (BD Biosciences) and culture media. Subcutaneous tumours were
16 implanted above the hind leg and tumour volumes were estimated longitudinally by
17 measuring the three tumour dimensions using a calliper and the hemi-ellipsoid
18 formula: volume = π · L ·W ·H/6, where L, W and H, are the tumour length, width
19 and height. Note that here, H, represents the measured height of the hemi-elliptical
20 tumour, which is half the height of a full ellipsoid. Eighteen days following cancer
21 cell implantation, subcutaneous tumours reached volumes of ∼50 mm3 prior to the
22 start of treatment. For orthotopic tumour implantation, animals were laid supine, a
23 small left abdominal ﬂank incision was made to exteriorize the pancreas and the cell
24 suspension was injected into the pancreas. A small amount of 10% povidone/iodine
25 was applied topically to the injection site. Then the incision was closed with 4–0
26 sutures and 10% povidone/iodine was then applied to the incision site to prevent
27 infection. Ten days after cancer cell implantation, orthotopic pancreatic tumours
28 reached volumes of ∼25 mm3 before the start of treatment. All injections for
29 treatment were done intravenously (tail vein) in 200 µl sterile phosphate-buffered
30 saline. Mice were randomized into the various treatment groups, and the tumours of
31 mice receiving BPD were irradiated with NIR light (using the 690 nm diode laser
32 listed above) 1 h post-injection, delivered at an irradiance of 100 mW cm−2.
33 Subcutaneous tumours were irradiated transcutaneously whereas orthotopic
34 tumours were surgically exposed as for tumour implantation and irradiated.
35 Fourteen days after treatment, orthotopic tumours were excised to estimate their
36 volumes using callipers and the ellipsoid formula above.
37 Microvessel immunoﬂuorescence imaging. Microvessel density and intratumoural
38 microvessel volume were estimated as described previously38. Brieﬂy, orthotopic
39 pancreatic tumours were excised 2 weeks post-treatment, embedded in optimal
40 cutting temperature compound and frozen at −80 °C. A cryotome was used to cut
41 20-μm-thick cryosections. Sections were (1) ﬁxed in 1:1 acetone:methanol for 15
42 min at −20 °C, (2) air dried for 30 min, and (3) washed three times in phosphate-
43 buffered saline. A blocking solution (Dako Protein Block Reagent) was applied for
44 30 min, followed by application of the immunostains, at ∼5 μg ml monoclonal
45 antibody (MAb) each diluted in background reducing Dako Antibody Diluent for
46 2 h at room temperature in a humidifying chamber. Finally, the slides were washed
47 again three times, mounted (Invitrogen SlowFade Gold with 4′,6-diamidino-2-
48 phenylindole, DAPI) with a coverslip and sealed with nail polish. Confocal
49 ﬂuorescence imaging was performed using an Olympus FluoView 1,000 confocal
50 microscope with a 10 × 0.4 numerical aperture (NA) or a 20 × 0.75 NA objective.
51 Excitation of DAPI, anti-mouse PECAM-1 (CD31; clone 390; CBL1337, Millipore)
52 MAb-Alexa Fluor 568 conjugates and anti-human cytokeratin 8 (clone LP3 K;
53 MAB3156, R&D Systems) MAb-Alexa Fluor 647 conjugates was carried out using
54 405-, 559- and 635-nm lasers, respectively. Mosaic images of entire tumour cross-
55 sections were collected and stitched together using the Olympus FluoView software.
56 The anti-human cytokeratin 8 stain (a cytoskeletal protein highly expressed by
57 AsPC1 cells) has dual selectivity for the epithelial cancer cells because it does not
58 react with mouse proteins. All analyses were performed using custom MATLAB
59 (Mathworks) routines for batch image processing38. Microvessel density values were
60 calculated from whole tumour sections, within viable tumour tissue only, and
61 averaged over slices from the entire tumour rather than a more complex ‘hot spot’
62identiﬁcation and calculation, which is difﬁcult to deﬁne objectively38. Intratumoural
63microvessel volume is calculated by multiplying microvessel density with the viable
64tumour volume in each slice and then summing over the whole tumour by
65interpolation38. Here, we used the minimum tumour subsampling necessary—based
66on a mathematical model—to resolve a statistically signiﬁcant change in
67intratumoural microvessel volume, as validated previously using the orthotopic
68AsPC1 tumour model38 (Supplementary Note 9).
69Measurement of metastatic burden. A quantitative reverse transcription–
70polymerase chain reaction (qRT-PCR) assay was performed on excised liver and iliac
71lymph nodes to estimate the number of human cancer cells in excised organs as
72described and validated previously44. Brieﬂy, qRT-PCR is used to measure the total
73number of human cancer cells from the level of human and mouse glyceraldehyde 3-
74phosphate dehydrogenase (GAPDH) housekeeping genes. At least 300 mg of freshly
75excised liver and retroperitoneal lymph nodes were collected at the treatment
76endpoint and snap frozen in liquid nitrogen. The frozen samples were then
77pulverized and homogenized, followed by RNA extraction (RNAeasy Plus Mini Kit;
78Qiagen). Human and mouse GAPDH gene were measured using custom synthesized
79primers (Invitrogen). For each specimen, the cycle threshold (Ct) from human
80GAPDH gene was normalized by Ct from mouse GAPDH gene. The normalized Ct
81was quantiﬁed into number of cancer cells using a standard curve generated with a
82set of organ lysates from no-tumour control mice mixed with different numbers of
83human cancer cells.
84Statistical analyses. Speciﬁc statistical tests are indicated in the ﬁgure captions and
85were carried out using GraphPad Prism (GraphPad Software). All reported P values
86are two-tailed. Parametric tests (one-way ANOVA with Tukey’s post hoc test) were
87used for in vitro drug release (Fig. 2f and Supplementary Fig. 4) and in vitro cell
88culture (Fig. 4b,c,d and Supplementary Fig. 6) studies; and, the D’Agostino &
89Pearson omnibus normality test (α = 0.05; requires n ≥ 8 replicates per group) did
90not identify signiﬁcant deviations from normality within these data sets (testing
91could only performed for groups with n ≥ 8 replicates). Note that all groups within
92the drug release data were analysed together (some groups appear only in
93Supplementary Fig. 4). Electron microscopy single-nanoparticle analysis (Fig. 3d)
94and all in vivo data (Figs. 5b,c,d, 6b,c,d and Supplementary Fig. 1) were analysed
95using nonparametric tests (the Mann-Whitney U test or Kruskal–Wallis one-way
96ANOVA). The Brown–Forsythe test (α = 0.05) was applied to all data sets with n ≥ 3
97replicates to test for equal variance (regardless of whether parametric or
98nonparametric analysis was used) and identiﬁed signiﬁcant deviations from equal
99variance (Figs. 3e, 5d and 6c). In these cases, the data were analysed following a
100logarithmic transform of the data to pass the Brown–Forsythe test. Two-way
101ANOVA was applied to test for synergistic treatment interactions50 (Fig. 5d)
102following a natural logarithm transform of the data to pass the D’Agostino &
103Pearson omnibus normality test. No exclusion criteria were used, and no data points
104or animals were excluded from analysis. Investigators were not blinded to
105experimental groups unless noted otherwise. Animal sample sizes were selected to
106ensure adequate power (80%) to detect a 20% difference using a maximum of 16
107animals per group assuming a standard deviation of 15%. For the subcutaneous
108model, signiﬁcance was achieved with 5 animals per group.
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